A
Avadel Pharmaceuticals plc (AVDL)
NGM – Real Time Price. Currency in USD
21.64
0.00 (0.00%)
Market open: Feb 11, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
21.64
0.00 (0.00%)
Market open: Feb 11, 2026, 4:00 PM EDT
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc.
There is no data to display
| Date | Type | Document |
|---|---|---|
| 2026-01-20 | 8-K | tm263598d1_8k.htm |
| 2026-01-12 | 8-K | tm262904d1_8k.htm |
| 2025-12-19 | DEFA14A | tm2534012d1_defa14a.htm |
| 2025-12-18 | 8-K | tm2533819d1_8k.htm |
| 2025-12-09 | 8-K | tm2533119d1_8k.htm |
| 2025-12-03 | DEFM14A | tm2529379-3_defm14a.htm |
| 2025-12-02 | PRER14A | tm2529379-2_prer14a.htm |
| 2025-11-19 | DEFA14A | tm2529228d12_defa14a.htm |
| 2025-11-17 | DEFA14A | tm2531449d1_8k.htm |
| 2025-11-14 | DEFA14A | tm2529228d10_defa14a.htm |